While retatrutide has generally been well-tolerated, clinical trials have also revealed a dose-dependent pattern with GI side effects
Here is a simple breakdown based on the 6-day half-life: After 6 days, 50% of the dose remains After 12 days, 25% remains After 18 days, 12.5% remains After 24 days, about 6% remains After 30 days, less than 4% remains In practice, most pharmacologists consider a drug effectively cleared after 5 half-lives
The triple agonist mechanism and why dose matters more than frequency Retatrutide is not just another GLP-1 medication
Symptoms may appear rapidly, or they may be subtle and easily dismissed this, combined with the fact that patients arent properly warned about these side effects, can result in severe outcomes for GLP-1 users
Zepbound is a GLP-1 and GIP receptor agonistoriginally approved for weight loss and diabetes management under the name tirzepatide